National Institute of Arthritis and Musculoskeletal and Skin Diseases at the National Institutes of Health, Bethesda, Maryland 20892, USA.
Ann N Y Acad Sci. 2009 Dec;1182:111-23. doi: 10.1111/j.1749-6632.2009.05159.x.
The role of the potent proinflammatory cytokine IL-1 in disease could clinically be investigated with the development of the IL-1 blocking agent anakinra (Kineret), a recombinant IL-1 receptor antagonist. It was first tested in patients with sepsis without much benefit but was later FDA approved for the treatment of patients with rheumatoid arthritis. More recently IL-1 blocking therapies are used successfully to treat a new group of immune-mediated inflammatory conditions, autoinflammatory diseases. These conditions include rare hereditary fever syndromes and pediatric and adult conditions of Still's disease. Recently the FDA approved two additional longer acting IL-1 blocking agents, for the treatment of cryopyrin-associated periodic syndromes (CAPS), an IL-1 dependent autoinflammatory syndrome. The study of autoinflammatory diseases revealed mechanisms of IL-1 mediated organ damage and provided concepts to a better understanding of the pathogenesis of more common diseases such as gout and Type 2 diabetes which show initial promising results with IL-1 blocking therapy.
在疾病中，强效促炎细胞因子 IL-1 的作用可以通过开发 IL-1 阻断剂 anakinra（Kineret），一种重组的 IL-1 受体拮抗剂来进行临床研究。它最初在败血症患者中进行了测试，但没有太大益处，但后来获得了 FDA 批准用于治疗类风湿关节炎患者。最近，IL-1 阻断疗法成功用于治疗一组新的免疫介导的炎症性疾病，自身炎症性疾病。这些疾病包括罕见的遗传性发热综合征以及儿科和成人斯蒂尔病。最近，FDA 批准了另外两种长效 IL-1 阻断剂，用于治疗 Cryopyrin 相关周期性综合征（CAPS），这是一种依赖于 IL-1 的自身炎症性综合征。自身炎症性疾病的研究揭示了 IL-1 介导的器官损伤的机制，并为更好地理解更常见的疾病（如痛风和 2 型糖尿病）的发病机制提供了概念，这些疾病在使用 IL-1 阻断疗法方面显示出了初步的有希望的结果。
